AGN-192403 free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 564957

CAS#: 175521-95-6 (free base)

Description: AGN-192403 hydrochloride is an I1 imidazoline binding site selective ligand with a potency at I1 comparable to moxonidine, but devoid of affinity for adrenoceptors and the I2 binding site.

Chemical Structure

img
AGN-192403 free base
CAS# 175521-95-6 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 564957
Name: AGN-192403 free base
CAS#: 175521-95-6 (free base)
Chemical Formula: C10H19N
Exact Mass: 153.15
Molecular Weight: 153.270
Elemental Analysis: C, 78.37; H, 12.50; N, 9.14

Price and Availability

Size Price Availability Quantity
10mg USD 345
50mg USD 955
Bulk inquiry

Related CAS #: 175521-95-6 (free base)   1021868-90-5 (HCl)    

Synonym: AGN-192403 free base; AGN192403; AGN 192403; AGN-192403

IUPAC/Chemical Name: (1S,2S,3S,4R)-3-isopropylbicyclo[2.2.1]heptan-2-amine

InChi Key: SHXVJSFOJHMEEQ-KATARQTJSA-N

InChi Code: InChI=1S/C10H19N/c1-6(2)9-7-3-4-8(5-7)10(9)11/h6-10H,3-5,11H2,1-2H3/t7-,8+,9+,10+/m1/s1

SMILES Code: CC([C@@H]1[C@@H](N)[C@H]2CC[C@@H]1C2)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 153.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Choi DH, Kim DH, Park YG, Chun BG, Choi SH. Protective effects of rilmenidine and AGN 192403 on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. Free Radic Biol Med. 2002 Nov 15;33(10):1321-33. doi: 10.1016/s0891-5849(02)01041-9. PMID: 12419464.


2: Chamberlain BT, Vincent M, Nafie J, Müller P, Greka A, Wagner FF. Multigram Preparation of BRD4780 Enantiomers and Assignment of Absolute Stereochemistry. J Org Chem. 2021 Mar 5;86(5):4281-4289. doi: 10.1021/acs.joc.0c02520. Epub 2021 Feb 22. PMID: 33618515.


3: Cobos-Puc LE, Aguayo-Morales H, Silva-Belmares Y, González-Zavala MA, Centurión D. α2A-adrenoceptors, but not nitric oxide, mediate the peripheral cardiac sympatho-inhibition of moxonidine. Eur J Pharmacol. 2016 Jul 5;782:35-43. doi: 10.1016/j.ejphar.2016.04.043. Epub 2016 Apr 22. PMID: 27112661.


4: Zádori ZS, Fehér Á, Al-Khrasani M, Lackó E, Tóth VE, Brancati SB, Hein L, Mátyus P, Gyires K. Imidazoline versus alpha₂-adrenoceptors in the control of gastric motility in mice. Eur J Pharmacol. 2013 Apr 5;705(1-3):61-7. doi: 10.1016/j.ejphar.2013.02.043. Epub 2013 Mar 13. PMID: 23499689.


5: Cobos-Puc L, Aguayo-Morales H, Ventura-Sobrevilla J, Luque-Contreras D, Chin- Chan M. Further analysis of the inhibition by agmatine on the cardiac sympathetic outflow: Role of the α2-adrenoceptor subtypes. Eur J Pharmacol. 2017 Jun 15;805:75-83. doi: 10.1016/j.ejphar.2017.03.009. Epub 2017 Mar 14. PMID: 28315344.


6: Cobos-Puc LE, Sánchez-López A, Centurión D. Pharmacological analysis of the cardiac sympatho-inhibitory actions of moxonidine and agmatine in pithed spontaneously hypertensive rats. Eur J Pharmacol. 2016 Nov 15;791:25-36. doi: 10.1016/j.ejphar.2016.08.017. Epub 2016 Aug 24. PMID: 27565220.


7: Yu Y, Koss MC. Rat clonidine mydriasis model: imidazoline receptors are not involved. Auton Neurosci. 2005 Jan 15;117(1):17-24. doi: 10.1016/j.autneu.2004.10.001. PMID: 15620566.


8: Rubio-Beltrán E, Labastida-Ramírez A, Hernández-Abreu O, MaassenVanDenBrink A, Villalón CM. Pharmacological analysis of the inhibition produced by moxonidine and agmatine on the vasodepressor sensory CGRPergic outflow in pithed rats. Eur J Pharmacol. 2017 Oct 5;812:97-103. doi: 10.1016/j.ejphar.2017.07.020. Epub 2017 Jul 8. PMID: 28694067.


9: Yang J, Sun N, Xiong Q, Yang R. Effect of moxonidine on the uveoscleral outflow: role of alpha2-adrenoceptors or i1 imidazoline receptors. Curr Eye Res. 2009 Apr;34(4):287-96. doi: 10.1080/02713680902750077. PMID: 19373577.


10: Fehér Á, Tóth VE, Al-Khrasani M, Balogh M, Lázár B, Helyes Z, Gyires K, Zádori ZS. Analysing the effect of I1 imidazoline receptor ligands on DSS-induced acute colitis in mice. Inflammopharmacology. 2017 Feb;25(1):107-118. doi: 10.1007/s10787-016-0299-7. Epub 2016 Nov 21. PMID: 27873165.


11: Zhou X, He D, Yan X, Chen X, Li R, Zhang G, Wang J. Moxonidine inhibits excitatory inputs to airway vagal preganglionic neurons via activation of both α2-adrenoceptors and imidazoline I1 receptors. Brain Res. 2020 Apr 1;1732:146695. doi: 10.1016/j.brainres.2020.146695. Epub 2020 Jan 31. PMID: 32007398.


12: Hayar A, Guyenet PG. Prototypical imidazoline-1 receptor ligand moxonidine activates alpha2-adrenoceptors in bulbospinal neurons of the RVL. J Neurophysiol. 2000 Feb;83(2):766-76. doi: 10.1152/jn.2000.83.2.766. PMID: 10669492.


13: Velliquette RA, Ernsberger P. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther. 2003 Aug;306(2):646-57. doi: 10.1124/jpet.103.050468. Epub 2003 May 19. PMID: 12756274.


14: Chao HM, Osborne NN. Topically applied clonidine protects the rat retina from ischaemia/reperfusion by stimulating alpha(2)-adrenoceptors and not by an action on imidazoline receptors. Brain Res. 2001 Jun 15;904(1):126-36. doi: 10.1016/s0006-8993(01)02499-4. PMID: 11516418.


15: Zádori ZS, Tóth VE, Fehér Á, Philipp K, Németh J, Gyires K. Evidence for the gastric cytoprotective effect of centrally injected agmatine. Brain Res Bull. 2014 Sep;108:51-9. doi: 10.1016/j.brainresbull.2014.07.008. Epub 2014 Aug 27. PMID: 25171957.


16: Sastre-Coll A, Esteban S, García-Sevilla JA. Effects of imidazoline receptor ligands on monoamine synthesis in the rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jul;360(1):50-62. doi: 10.1007/s002109900032. PMID: 10463334.


17: Raasch W, Jungbluth B, Schäfer U, Häuser W, Dominiak P. Norepinephrine release is reduced by I(1)-receptors in addition to alpha(2)-adrenoceptors. Ann N Y Acad Sci. 2003 Dec;1009:270-3. doi: 10.1196/annals.1304.034. PMID: 15028598.


18: Schäfer U, Burgdorf C, Engelhardt A, Raasch W, Kurz T, Richardt G. Moxonidine displays a presynaptic alpha-2-adrenoceptor-dependent synergistic sympathoinhibitory action at imidazoline-1 receptors. Ann N Y Acad Sci. 2003 Dec;1009:265-9. doi: 10.1196/annals.1304.033. PMID: 15028597.


19: Mukaddam-Daher S, Menaouar A, Gutkowska J. Receptors involved in moxonidine- stimulated atrial natriuretic peptide release from isolated normotensive rat hearts. Eur J Pharmacol. 2006 Jul 10;541(1-2):73-9. doi: 10.1016/j.ejphar.2006.05.009. Epub 2006 May 12. PMID: 16774751.


20: Cobos-Puc LE, Villalón CM, Ramírez-Rosas MB, Sánchez-López A, Lozano-Cuenca J, Gómez-Díaz B, MaassenVanDenBrink A, Centurión D. Pharmacological characterization of the inhibition by moxonidine and agmatine on the cardioaccelerator sympathetic outflow in pithed rats. Eur J Pharmacol. 2009 Aug 15;616(1-3):175-82. doi: 10.1016/j.ejphar.2009.06.003. Epub 2009 Jun 13. PMID: 19527708.